within Pharmacolibrary.Drugs.ATC.J;

model J01RA16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01RA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefixime is a third-generation oral cephalosporin antibiotic, and azithromycin is a macrolide antibiotic. The fixed-dose combination is used primarily for the treatment of uncomplicated gonorrhea and other sexually transmitted infections due to their synergistic antibacterial effects. This combination is currently approved and in clinical use in several regions.</p><h4>Pharmacokinetics</h4><p>No published studies providing direct pharmacokinetic parameters for the fixed-dose combination of cefixime and azithromycin (J01RA16) were identified. The following values are estimated based on pharmacokinetic data for the individual drugs in healthy adults, given as a single oral dose.</p><h4>References</h4><ol><li><p>Tantalo, LC, et al., &amp; Mitjà, O (2023). Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study. <i>The Lancet. Microbe</i> 4(12) e994–e1004. DOI:<a href=&quot;https://doi.org/10.1016/S2666-5247(23)00219-7&quot;>10.1016/S2666-5247(23)00219-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37827185/&quot;>https://pubmed.ncbi.nlm.nih.gov/37827185</a></p></li><li><p>Scaglione, F, et al., &amp; Fraschini, F (1999). Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin. <i>British journal of clinical pharmacology</i> 47(3) 267–271. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1999.00887.x&quot;>10.1046/j.1365-2125.1999.00887.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10215750/&quot;>https://pubmed.ncbi.nlm.nih.gov/10215750</a></p></li><li><p>Drusano, GL, &amp; Craig, WA (1997). Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. <i>Journal of chemotherapy (Florence, Italy)</i> 9 Suppl 3 38–44. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9248979/&quot;>https://pubmed.ncbi.nlm.nih.gov/9248979</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01RA16;
